Retrospective review of old patients~Analysis of prediction factors for concomitant chemo-radiotherapy in locally advanced and advanced esophageal cancer from 2005 to 2015~Study Group~non responder~CR but recurrence~CR and survival loner than 2 years~Prospective case-control study: RNA sequencing & miRNA microarray~naive esophageal cancer patients who have a plan to receive concomitant chemo-radiotherapy --> acquirement of tissue, blood, clinical information --> isolation of RNA, DNA, serum database of clinical & demographic information~study group~non-responder (N=14)~Complete Remission (N=14)~For considering the drop rate, 2-fold screening~***Analysis of mRNA sequencing / miRNA sequencing**** first analysis of RNA sequencing: bioinformatician second analysis of RNA sequencing: principle investigator~3) Experimental set for qPCR (esophageal tissue) study group~non-responder (N=40)~complete remission (N=40)~4) TMA for screened exon gene~5) validation set for qPCR (esophageal tissue) new esophageal cancer set~non-responder (N=30)~complete remission (N=30)~6) follow-up of circulating miRNA in blood (baseline blood & post-CCRT blood 3M, 6M, 12M)~7) Prediction model for CCRT response in esophageal Cancer based on clinical and molecular factors~Test several combination models~gene + gene combination,~gene + clinical information combination,~gene + gene + clinical information combination~8) Validate the prediction model.~9) primary organoid culture and prediction of chemoradiotherapy response
Retrospective review of old patients~Analysis of prediction factors for concomitant chemo-radiotherapy in locally advanced and advanced esophageal cancer from 2005 to 2015~Prospective case-control study: RNA sequencing & miRNA microarray~naive esophageal cancer patients who have a plan to receive concomitant chemo-radiotherapy~acquirement of tissue, blood, clinical information~isolation of RNA, DNA, serum database of clinical & demographic information~***Analysis of mRNA sequencing / miRNA sequencing**** first analysis of RNA sequencing: bioinformatician second analysis of RNA sequencing: principle investigator~Experimental set for qPCR (esophageal tissue) study group~TMA for screened exon gene~validation set for qPCR (esophageal tissue)~follow-up of circulating miRNA in blood (baseline blood & post-CCRT blood 3M, 6M, 12M)~Prediction model for CCRT response in esophageal Cancer based on clinical and molecular factors~Validate the prediction model.